Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Modular Phase II Study to Link Targeted Therapy to Patients With Pathway Activated Tumors: Module 4 - LGX818 for Patients With BRAFV600 Mutated Tumors

NCT01981187 is registered in ClinicalTrials.gov with Pfizer as lead sponsor.

NCT NCT01981187
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01981187 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Modular Phase II Study to Link Targeted Therapy to Patients With Pathway Activated Tumors: Module 4 - LGX818 for Patients With BRAFV600 Mutated Tumors
Lead sponsor
Pfizer
Phase
Phase 2
Overall status
Terminated
Start date
January 14, 2014
Completion date
October 13, 2015
Enrollment
12 (actual)
Sites
13

Conditions

As the registry lists them; a condition with its own page is linked.

hematologic malignancies, solid tumor